Aptose Announces Results from Special Meeting of Shareholders

Core Viewpoint - Aptose Biosciences Inc. held a special meeting of shareholders on September 5, 2024, where key proposals regarding the issuance of common shares and potential adjournments were approved by the requisite number of votes [1]. Proposal Summary - Proposal No. 1: Approval of the issuance of common shares underlying certain warrants was passed with 3,969,105 votes in favor, representing 93.34% of the votes cast [3]. - Proposal No. 2: Approval for one or more adjournments of the meeting was also passed, with 97.05% of votes in favor [3]. Voting Results - A total of 6,052,460 common shares were voted, accounting for 33.42% of the issued and outstanding shares [1][3]. - The breakdown of votes for Proposal No. 1 included 3,969,105 votes for, 267,013 against, and 16,342 withheld/abstained [3]. - The total shares issued and outstanding were reported as 18,109,393, with 1,800,000 shares held by insiders excluded from the voting results [3]. Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [4]. - The lead compound, tuspetinib, is an oral kinase inhibitor targeting acute myeloid leukemia (AML) and is being developed for both monotherapy and combination therapy [4].